An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521642-14-00

Enrollment

Registered

2026-02-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple System Atrophy

Brief summary

The primary safety and tolerability endpoints are as follows: • number (%) of participants experiencing an adverse event, The primary safety and tolerability endpoints are as follows: • number (%) of participants who withdraw from the trial due to an adverse event

Interventions

DRUGEmrusolmin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary safety and tolerability endpoints are as follows: • number (%) of participants experiencing an adverse event, The primary safety and tolerability endpoints are as follows: • number (%) of participants who withdraw from the trial due to an adverse event	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 5, 2026